FGFR3IIIS: A New Variant Linked to Tumor Growth
Author Information
Author(s): Sturla L-M, Merrick A E, Burchill S A
Primary Institution: Candlelighter's Children's Cancer Research Laboratory, Cancer Research UK Clinical Centre, St. James's University Hospital
Hypothesis
The study investigates the expression and role of a novel FGFR3 splice variant, FGFR3IIIS, in tumor cells.
Conclusion
FGFR3IIIS is frequently expressed in tumor cells and may inhibit growth and differentiation by acting as a dominant-negative variant.
Supporting Evidence
- FGFR3IIIS was detected in 57% of primary tumors studied.
- FGFR3IIIS mRNA encodes a protein that is co-expressed with FGFR3IIIc.
- Knockout of FGFR3IIIS decreased viable cell number in TC-32 cells.
Takeaway
Researchers found a new version of a protein that can help tumors grow, and this version is usually not found in normal cells.
Methodology
The study used RT-PCR to detect FGFR3 splice variants in various tumor cell lines and patient samples.
Potential Biases
Potential bias in sample selection and the interpretation of splice variant significance.
Limitations
The study primarily focuses on a limited number of tumor types and cell lines.
Participant Demographics
Patients treated at St James's University Hospital between 1992 and 1998.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website